Artificial axons as a myelination assay for drug screening in neurological diseases

Year 2019
Project team Krystyn Van Vliet & Nicholas Fang with Anna Jagielska, Kavin Kowarski, Daniela Espinosa-Hoyos, Huifeng Du and Seok Kim
Challenging to find cures for neurological disease
Lack of platforms that credibly represent neural tissue
More predictive In-vitro drug development

Better representation of neural tissue

Finding cures for neurological diseases is challenging. Most drug candidates fail in clinical trials, in part due to the lack of adequate in vitro drug screening platforms that credibly represent the neural tissue environment. This team is developing artificial axons, a novel drug-screening platform that mimics biological and mechanical properties of neuronal axons. By providing a better representation of neural tissue, this platform will allow for more predictive in vitro drug development, accelerating finding cures for neurological diseases

3 Questions: Anna Jagielska on printing artificial axons

Anna discussed with us how 3D-printed models of neuronal axons could accelerate development of new therapies to treat neurodegenerative disorders.

Anna Jagielska presents Artificial Axons: Biofidelic Drug Screening Platform for Neurological Diseases at IdeaStream 2021.
Anna Jagielska presents Artificial Axons As a Myelination Assay for Drug Screening in Neurological Diseases at IdeaStream 2020.